Company intelligence / Profile preview

TransMolecular

Birmingham, Alabama, United States

Ownership: Private
Development stage: Phase 2

Overview

TransMolecular was a biotechnology company focused on developing novel drugs for cancer treatment, particularly targeting disorders of the central nervous system. Their pipeline included TM-604 for neoplasms and chlorotoxin-based therapies for glioblastoma multiforme.

Therapeutic areas: Oncology
Modalities: Synthetic peptide
Industry: Biotech

Drug pipeline

2 assets

131i-tm601

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on TransMolecular.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TransMolecular.

Explore the full profile